Really enjoyed participating in this podcast @bloodjournals.hematology.org on new #targetedtherapies in #MPN including #mutantcalreticulin #MPNsm @stanforddeptmed.bsky.social @ash.hematology.org @mpnrf.bsky.social @stanfordmedicine.bsky.social
Full episode! We speak with Stingray Therapeutics' CEO and Co-founder Jon Northrup. The company is developing a checkpoint inhibitor called vizenpistat which inhibits the ENPP1 enzyme.
#Biotechnology #OncologyInnovation #CancerResearch #TargetedTherapies
youtu.be/BlMJSYStzLE
"Be here now, in the moment." Terri Conneran
Thank you for this amazing presentation!
#LungCancer #PatientAdvocate #KRAS #LungCancerSurvivor #TargetedTherapies #GRACE #KRASKickers
#Neladalkib: A Fourth Generation TKI.
#LungCancerTreatment #TargetedTherapies #ALK #TKI
Isabel Preeshagul
Now presenting Dr. Isabel Preeshagul: "ALK, ROS1 and RET Mutations".
Join us at give.cancergrace.org/event/lung-c...
#LungCancer #ALK #ROS1 #RET #TargetedTherapies #GRACE
Do you want to learn more about #BRAF?
Join us now at our Lung Cancer Targeted Therapies OncTalk!
#LungCancer #TargetedTherapies #V600E #NSCLC #GRACE #LungCancerInformation
Now presenting Dr. Christina Baik:
"KRAS and BRAF mutated NSCLC".
#TargetedTherapies #LungCancer #GRACE #KRAS #NSCLC #BRAF
"Any drug that targets #EGFR will, to some degree, have these #sideeffects." - Tejas Patil
#LungCancerTargetedTherapies #LungCancer #TargetedTherapies
We are back!
Now presenting: @TejasPatilMD. "We have come a long way. What the Lung Cancer Community Needs to Know about EGFR and HER2 Mutations."
Join us now!
give.cancergrace.org/event/lung-c...
#LungCancer #TargetedTherapies #LungCancerInformation #GRACE
Dr. Suraj Samtani, now presenting: "Diagnosis and Treatment of Cancer Cachexia in Lung Cancer".
The Unignorable Numbers
Lung cancer remains the leading cause of cancer mortality in the United States, with cachexia compounding the challenge at every stage.
#LungCancer #TargetedTherapies #Cachexia
Targeted Therapy vs Traditional Chemotherapy?
Don't miss this valuable information. If you know someone who might benefit from this amazing event on Lung Cancer Targeted Therapies, please share this event with them!
#LungCancer #TargetedTherapies #Chemotherapy
What are the different types of Targeted Therapies?
Now presenting Dr. Sonam Puri.
#LungCancer #TargetedTherapies #KinaseInhibitors #BispecificAntibodies
Questions to ask your doctor from Dr. @AHerrmannMD presentation!
#MolecularTesting #LungCancer #TargetedTherapies #cancerGRACE
#TrueOrFalse
Having molecular testing results back to inform treatment decision-making before starting systemic therapy is associated with improved survival.
Join us at give.cancergrace.org/event/lung-c... and find out if this is true or false!
#LungCancer #TargetedTherapies
What are the differences between Molecular circulating tumor DNA (ctDNA) testing and minimal residual disease (MRD) testing?
Now presenting Dr. @Joshua_Reuss!
#LungCancer #TargetedTherapies #TrueOrFalse #Molecularprofiling #MRDTesting #ctDNATesting
#ESMOTAT26: Around half of patients treated with #TargetedTherapies according to ESCAT tier I and tier II survived for at least 12 months in early-phase ClinicalTrials within the 360 RESISTANCE study. Read more in the #ESMODailyReporter 📌 https://ow.ly/jIoQ50YvfMT
CEO Jon Northrup introduces the adaptive and innate immune systems. He describes Stingray Therapeutics’ ENPP1 inhibitor which has shown potential in activating the innate immune system in cancer patients.
youtube.com/shorts/dgoX7...
#Biotechnology #CancerResearch #TargetedTherapies
Stingray Therapeutics’ CEO Jon Northrup likens the immune system to Neo in the Matrix. Its checkpoint inhibitor, vizenpistat, complements the immune system’s fight against cancer. youtube.com/shorts/1PFjL...
#CancerResearch #TargetedTherapies #PrecisionMedicine #ImmunoOncology #LifeSciences
New paper w/Paul Martin & Jin Ding: “Why is the pharmaceutical industry investing in targeted therapies? The emergence of “premium pharma" | How #orphandrugs #ATMPs #TargetedTherapies reshape #BioPharmaInnovation #HTA sciencedirect.com/science/article/pii/S0277953625012195 @sheffielduni.bsky.social
Don’t miss Drs. Wakelee, Yu and Behl on 2/19 at 8 PM PST during #TTLC26 for a live symposium on personalizing treatment in advanced #NSCLC, with a focus on emerging #Immunotherapy and #TargetedTherapies data. Join in person or virtually: https://bit.ly/LungCancer26-Sky
⏰ Early registration for #ESMOTAT26 ends 28 Jan!
Join a leading multi-stakeholder forum on cancer #drugdiscovery in Paris.
🔗 Register now: https://ow.ly/VQce50XWy9H
#ESMOMeetings #targetedtherapies #PrecisionMedicine #ClinicalTrials
CEO Dr Bianco shares TuHURA's work with the #FDA's Oncology Center of Excellence to construct a trial to satisfy requirements for accelerated & full approval of IFx-2.0 in Merkel Cell Carcinoma
$HURA
#TuhuraBio #Bioscience #LifeSciences #Oncology #TargetedTherapies
youtube.com/shorts/eeS09...
🧬 New insights into #AML: A study led by @floriangrebien.bsky.social identifies #SPOP as a key regulator of #NUP98 fusion oncoprotein stability, highlighting a potential new avenue for #TargetedTherapies.
www.cell.com/cell-reports...
@cemm.oeaw.ac.at
@stanna-ccri.bsky.social
Unlock the Future of Cancer Treatment!
Explore how targeted therapies and advanced diagnostics are reshaping cancer care across Europe.
Hear from leading experts Professors Frederique Penault-Llorca and Pascal Pujol
👉 www.dxrx.io/articles/art...
#CancerCare #TargetedTherapies #Diagnostics
👨🔬👩🔬 We're thrilled to announce that #MedChemExpress will be exhibiting at the #AACR-NCI-EORTC International Conference on Molecular Targets and #Cancer Therapeutics.
📆 October 22–26, 2025
📍 Hynes Convention Center, Boston, MA.
🔽 For More Information:
lnkd.in/gEWR25pd
#ADC #TargetedTherapies
#ESMO25: Paradigm shifts are occurring in the management of metastatic mutated #NSCLC. Alfredo Addeo describes some of the innovative #TargetedTherapies and combinations that are improving patient outcomes.
#ESMODailyReporter ➡️ https://ow.ly/IWOr50XeTfh
#LungCancer
Alfredo Addeo
📣 Abstract submission is open for #ESMOTAT26
Showcase your research in #Cancer #DrugDiscovery & #TargetedTherapies.
Deadline: 16 December
🔗 Submit now: buff.ly/a4kXwWN
We are thrilled to announce #NDLR2026 speaker Dr Julie Thoms, from UNSW . Julie's research interests lie in understanding #GeneRegulation in #Leukemia driving stem cells to develop #TargetedTherapies.
#BloodCancer #CancerResearch #MyelodysplasticSyndromes #AcuteMyeloidLeukemia
